Book a Meeting

Non-fucosylated Anti-Human CD20 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ03] (CAT#: BioBet-003ZP) Datasheet

Human Antibody
ADCC-enhanced Ofatumumab is a non-fucosylated anti-CD20 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-CD20 Ofatumumab, a biobetter by reducing fucosylation of the Fc region of Ofatumumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Chronic lymphocytic leukaemia
Phase IIIB-cell lymphoma
Diffuse large B cell lymphoma
Follicular lymphoma
Multiple sclerosis
Phase II Marginal zone B-cell lymphoma
Precursor cell lymphoblastic leukaemia-lymphoma
Therapeutic antibody; biobetter
Date of FDA Approval (Patent Expiration): 2009 (2023)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Ofatumumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Full Name
membrane spanning 4-domains A1
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
Alternative Names
B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16
Gene ID
UniProt ID
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with MS4A1 include Immunodeficiency, Common Variable, 5 and Common Variable Immunodeficiency.
Related Pathways
Its related pathways are Hematopoietic cell lineage and Hematopoietic Stem Cells and Lineage-specific Markers.
b lymphocyte-specific membrane protein, which is involved in the regulation of cellular calcium influx necessary for the development, differentiation and activation of b lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111). After activation of b-cell receptor/BCR, it acts as a component of stored and operated calcium (SOC) channels to promote calcium influx (PubMed:7684739, PubMed:12920111, PubMed:18474602).
Field of research
Cancer antibody; Developmental Biology antibody; Immune System antibody; B cell Marker antibody; Immature B Cell Marker antibody; Inflammatory Cell Marker antibody; Tumor-infiltrating Lymphocyte Study antibody
Post-translational modifications
Phosphorylated. Might be functionally regulated by protein kinase(s).
Trade name
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
CAS number
Antibody Isotype
Human Antibody
Antibody Clone
Ofatumumab's first human monoclonal antibody targeting the CD20 molecule was approved by the FDA in 2014 for the treatment of refractory chronic lymphocytic leukemia. It appears to inhibit the activation of early B lymphocytes, showing potential for treating follicular lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing multiple sclerosis. This antibody can be used in patients with refractory CLL.
Chronic lymphocytic leukaemia
Phase IIIB-cell lymphoma
Diffuse large B cell lymphoma
Follicular lymphoma
Multiple sclerosis
Phase II Marginal zone B-cell lymphoma
Precursor cell lymphoblastic leukaemia-lymphoma

Ofatumumab is an anti-CD20 human monoclonal antibody that binds unique epitopes on CD20 with high specificity. CD20 antigen is expressed only on B-cell lymphocytes. CD20 antigen is expressed only on B-cell lymphocytes. Compared to rituximab, ofatumumab binds more tightly to CD20 and has a lower shut-down rate. It causes cytotoxicity in cells expressing CD20 through complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC).
Blood cancers
Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukemia (CLL) - Refractory
Autoimmune diseases
Rheumatoid Arthritis

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *